| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/17/2003 | WO2003018546A3 Tricyclic pyridin-2-one analogues as ligands for gaba-a receptors |
| 07/17/2003 | WO2003008410A3 Polypyrroles as agents for treating cancer, treating viral diseases and causing immunosuppression |
| 07/17/2003 | WO2003000896A3 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 07/17/2003 | WO2002094259B1 Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation |
| 07/17/2003 | WO2002059286A3 Adenylate cyclases |
| 07/17/2003 | WO2002058323A3 Method for identifying modulators of bace |
| 07/17/2003 | WO2002055693A3 Method for inhibiting the expression of a target gene |
| 07/17/2003 | WO2002049663A3 Compositions and methods for manipulating glial progenitor cells and treating neurological deficits |
| 07/17/2003 | WO2002046190A3 Sulfonamido ether substituted imidazoquinolines |
| 07/17/2003 | WO2002039947A3 Carrier vectors through an epithelium with tight junctions |
| 07/17/2003 | WO2002031134A3 Novel serine protease genes related to dppiv |
| 07/17/2003 | WO2002029060A9 Hematopoietin receptors hpr1 and hpr2 |
| 07/17/2003 | WO2002026998A3 Hydrolases |
| 07/17/2003 | WO2002022805A3 Modulation of il-2- and il-15-mediated t cell responses |
| 07/17/2003 | WO2002011713A3 Methods of treating bone cancer and the pain associated therewith using endothelin antagonists |
| 07/17/2003 | WO1999044581A3 Pharmaceutical composition of topiramate |
| 07/17/2003 | US20030135044 Novel gamma secretase inhibitors |
| 07/17/2003 | US20030135043 Novel synthesis and crystallization of piperazine ring-containing compounds |
| 07/17/2003 | US20030135042 Atypical antipsychotic agents having low affinity for the D2 Receptor |
| 07/17/2003 | US20030134906 Modified release pharmaceutical composition containing bupropion HCI as active substance |
| 07/17/2003 | US20030134902 Novel dicarboxylic acid derivatives |
| 07/17/2003 | US20030134895 Method for the preparation of citalopram |
| 07/17/2003 | US20030134891 N,N'-bis(2-carboxytetramethylene)adipamide or cyclic alkylene esters for use in the treatment or prevention of central and systemic amyloidosis. |
| 07/17/2003 | US20030134888 Substituted diaminopyrazoles; treating diseases, such as cancer, inflammatory disorders, restenosis, and cardiovascular disease. coatings for implantable medical devices, such as prostheses, artificial valves, etc. |
| 07/17/2003 | US20030134887 Orally administering celecoxib formulated in such a way as to provide a blood plasma concentration profile of celecoxib of 250 ng/ml in not later than 30 minutes |
| 07/17/2003 | US20030134886 Pharmaceutically active compounds |
| 07/17/2003 | US20030134878 Use of a compound in providing refreshedness on waking and a method for the treatment of drowsiness therewith |
| 07/17/2003 | US20030134873 8-phenyl-(1,2,4)triazolo(1,5-a)pyridin-2-yl)-benzamide derivatives |
| 07/17/2003 | US20030134869 Novel therapeutic use of nicergoline |
| 07/17/2003 | US20030134868 Prevention of addiction in pain management |
| 07/17/2003 | US20030134863 Preventives/remedies for alzheimer's disease |
| 07/17/2003 | US20030134861 Transmucosal phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 07/17/2003 | US20030134859 Substituted 2-chloro-5-nitrobenzamides; treating retrograde osteoporosis and diabetes mellitus |
| 07/17/2003 | US20030134858 Treatment of inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease |
| 07/17/2003 | US20030134855 P-acylaminomethyl-N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2 -yl)-benzamides; treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, Parkinson's and ADHD |
| 07/17/2003 | US20030134854 Treatment of diseases related to the adenosine receptor, such as Alzheimer's disease, depression, drug addiction, neuroprotection, Parkinson's disease, and attention deficit hyperactivity disorder. |
| 07/17/2003 | US20030134852 Halogen substituted tetracyclic tetrahydrofuran derivatives |
| 07/17/2003 | US20030134850 Hydrazinyl and nitrogen oxide pyrazoles |
| 07/17/2003 | US20030134849 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors |
| 07/17/2003 | US20030134848 Substituted 1-aza-2-imino-heterocycles and their use as nicotinic acetylcholin receptors activators |
| 07/17/2003 | US20030134847 New polycyclic azaindole compounds |
| 07/17/2003 | US20030134839 5-(Alkylidene-cycloalkyl)-and 5-(alkylidene-heterocyclyl)-pyrazoles |
| 07/17/2003 | US20030134837 Pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them and anticancer agents |
| 07/17/2003 | US20030134836 Substituted arylamine derivatives and methods of use |
| 07/17/2003 | US20030134829 X is a ring having at least 4 atoms in the ring; K is hydrocarbyl group; Rh1 is an optional halo group; Rh2 is an optional halo group; at least one of Rh1 and Rh2 is present; Rs is any one of a sulphamate group, a phosphonate, |
| 07/17/2003 | US20030134810 Delivery of pharmacologically active agents associated with polymeric biocompatible materials. Compositions comprising a first, negatively charged pharmacologically active agent such as an oligonucleotide and a polycationic polymer such as |
| 07/17/2003 | US20030134800 Physiologically active substance in high content, suppressing the initial excess release, and achieving a stable release speed over a long period of time is provided. composition weight, (2) hydroxynaphthoic acid |
| 07/17/2003 | US20030134799 Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function |
| 07/17/2003 | US20030134430 Novel amino acid sequences for human caenorhabditis elegans-like protein polypeptides |
| 07/17/2003 | US20030134414 Ligating a peripheral nerve, then excising material rich in glial cells, providing a support matrix and inserting into spinal cords |
| 07/17/2003 | US20030134387 Vertebrate globin |
| 07/17/2003 | US20030133999 Polar solvent extract of Polygala, polar solvent being water or a mixture of water and methanol or ethanol |
| 07/17/2003 | US20030133985 Controlled release oral dosage forms; data obtained using disintegration test such as the established USP Disintegration Test, rather than the results obtained using a standard USP Dissolution Test, as is conventionally done |
| 07/17/2003 | US20030133977 Method of systemically delivering SSRIs |
| 07/17/2003 | US20030133951 Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines |
| 07/17/2003 | US20030133930 Administering to a patient having an autoimmune disorder an antibody to a B-cell antigens and a carrier; CD22, CD20, CD19, and CD74 or HLA-DR antigen. |
| 07/17/2003 | US20030133913 Producing chemokine receptors, inducing antigen by dendritic cells in vitro, for therapeutic or prophylactic purposes |
| 07/17/2003 | US20030133875 Assay for screening candidate drug for the treatment of inflammatory diseases and methods for treating the same |
| 07/17/2003 | DE20305138U1 Medicament, useful for the treatment of amyotrophic lateral sclerosis and for improving motor activity, comprises a melatonin compound |
| 07/17/2003 | CA2473097A1 Compositions including ammonia oxidizing bacteria and methods of using same |
| 07/17/2003 | CA2473043A1 Pharmaceutical composition comprising a glitazone and a 4-oxobutanoic acid, and the use thereof for treating diabetes |
| 07/17/2003 | CA2472617A1 Substituted amino carboxamides for the treatment of alzheimer's disease |
| 07/17/2003 | CA2472585A1 Drug mixture with enhanced dissolution rate |
| 07/17/2003 | CA2472331A1 Process and intermediates for pyridazinone antidiabetic agents |
| 07/17/2003 | CA2472165A1 3,4-di-substituted pyridazinediones as cxc chemokine receptor antagonists |
| 07/17/2003 | CA2472118A1 Pak5-related compositions and methods |
| 07/17/2003 | CA2472111A1 Human mast cell-expressed membrane proteins |
| 07/17/2003 | CA2472049A1 Dominant negative proteins and methods thereof |
| 07/17/2003 | CA2471951A1 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/17/2003 | CA2471947A1 Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
| 07/17/2003 | CA2471885A1 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | CA2471880A1 1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
| 07/17/2003 | CA2471504A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 07/17/2003 | CA2471204A1 Inhibitors of dipeptidyl peptidase iv |
| 07/17/2003 | CA2470012A1 Novel proteins and nucleic acids encoding same |
| 07/17/2003 | CA2469480A1 Use of biomolecular targets in the treatment and visualization of tumors |
| 07/17/2003 | CA2469162A1 Composition inhibiting matrix-metallproteinases for the treatmentof neoplastic diseases |
| 07/16/2003 | EP1327630A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
| 07/16/2003 | EP1327446A1 Controlled release oxycodone compositions |
| 07/16/2003 | EP1327445A1 Controlled release oxycodone compositions |
| 07/16/2003 | EP1327441A1 Chewing gum composition for eliminating nicotine, containing plant extracts and polyphenols such as catechin or quercetin |
| 07/16/2003 | EP1326990A2 Packaging of positive-strand rna virus replicon particles |
| 07/16/2003 | EP1326987A1 Chimeric cytoplasmic signalling molecules derived from cd137 |
| 07/16/2003 | EP1326986A2 Regulation of human sphingosine kinase-like protein |
| 07/16/2003 | EP1326978A2 Hematopoietin receptors hpr1 and hpr2 |
| 07/16/2003 | EP1326972A2 Transporters and ion channels |
| 07/16/2003 | EP1326971A2 Proteins and nucleic acids encoding same |
| 07/16/2003 | EP1326896A2 Human anti-cd40 antibodies |
| 07/16/2003 | EP1326869A1 Pyrrole-condensed morphinoid derivatives |
| 07/16/2003 | EP1326868A1 Morphinoid derivatives as delta-opioid agonists and antagonists |
| 07/16/2003 | EP1326867A2 Bridged piperazine derivatives |
| 07/16/2003 | EP1326866A1 Substituted 3.4-dihydro-pyrido[1,2-a]pyrimidines |
| 07/16/2003 | EP1326864A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 07/16/2003 | EP1326863A2 Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines |
| 07/16/2003 | EP1326861A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 07/16/2003 | EP1326859A1 Quinazoline derivatives with anti-tumour activity |
| 07/16/2003 | EP1326858A2 Piperidine compounds as anti-allergic |
| 07/16/2003 | EP1326853A1 New thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors |
| 07/16/2003 | EP1326849A1 Benzodiazepine derivatives as inhibitors of gamma secretase |
| 07/16/2003 | EP1326848A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |